Apellis (APLS) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
781.4M
Gross Profit
663.6M
84.93%
Operating Income
-165.0M
-21.11%
Net Income
-197.9M
-25.32%
Balance Sheet Metrics
Total Assets
885.1M
Total Liabilities
656.5M
Shareholders Equity
228.5M
Debt to Equity
2.87
Cash Flow Metrics
Operating Cash Flow
-128.4M
Free Cash Flow
-88.3M
Revenue & Profitability Trend
Apellis Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 781.4M | 396.6M | 75.4M | 66.6M | 250.6M |
| Cost of Goods Sold | 117.7M | 58.5M | 5.6M | 5.2M | 25.0M |
| Gross Profit | 663.6M | 338.1M | 69.8M | 61.4M | 225.6M |
| Operating Expenses | 828.6M | 855.2M | 664.4M | 597.6M | 439.3M |
| Operating Income | -165.0M | -517.1M | -594.6M | -536.3M | -213.7M |
| Pre-tax Income | -196.7M | -526.5M | -651.5M | -746.0M | -343.0M |
| Income Tax | 1.2M | 2.1M | 669.0K | 352.0K | 1.8M |
| Net Income | -197.9M | -528.6M | -652.2M | -746.4M | -344.9M |
| EPS (Diluted) | - | -$4.45 | -$6.15 | -$8.84 | -$4.59 |
Income Statement Trend
Apellis Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 789.0M | 766.3M | 719.5M | 824.0M | 917.2M |
| Non-Current Assets | 96.1M | 22.4M | 40.7M | 57.7M | 43.4M |
| Total Assets | 885.1M | 788.7M | 760.2M | 881.8M | 960.6M |
| Liabilities | |||||
| Current Liabilities | 185.5M | 247.6M | 167.6M | 131.8M | 128.3M |
| Non-Current Liabilities | 471.0M | 346.6M | 422.7M | 551.3M | 627.7M |
| Total Liabilities | 656.5M | 594.2M | 590.3M | 683.1M | 756.0M |
| Equity | |||||
| Total Shareholders Equity | 228.5M | 194.5M | 169.9M | 198.7M | 204.6M |
Balance Sheet Composition
Apellis Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -197.9M | -528.6M | -652.2M | -746.4M | -344.9M |
| Operating Cash Flow | -128.4M | -627.9M | -528.8M | -737.5M | -345.2M |
| Investing Activities | |||||
| Capital Expenditures | -403.0K | -674.0K | -1.5M | -1.1M | -5.4M |
| Investing Cash Flow | -403.0K | -674.0K | 59.9M | 247.6M | -317.0M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 130.4M | 317.8M | 339.9M | 374.6M | 681.2M |
| Free Cash Flow | -88.3M | -595.5M | -515.3M | -564.2M | -165.9M |
Cash Flow Trend
Apellis Key Financial Ratios
Valuation Ratios
Forward P/E
-20.98
Price to Book
13.48
Price to Sales
2.85
PEG Ratio
-20.98
Profitability Ratios
Profit Margin
-28.83%
Operating Margin
-49.96%
Return on Equity
-103.82%
Return on Assets
-14.20%
Financial Health
Current Ratio
4.08
Debt to Equity
285.94
Beta
0.67
Per Share Data
EPS (TTM)
-$1.80
Book Value per Share
$1.31
Revenue per Share
$6.23
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| apls | 2.2B | - | 13.48 | -103.82% | -28.83% | 285.94 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Blueprint Medicines | 8.3B | -120.00 | 24.19 | -47.71% | -27.70% | 208.50 |
| Roivant Sciences | 7.8B | 1.95 | 1.71 | -12.54% | 96.86% | 1.93 |
| Bio-Techne | 7.9B | 60.87 | 3.92 | 6.53% | 10.89% | 20.99 |
Financial data is updated regularly. All figures are in the company's reporting currency.